Decline in Invasive Pneumococcal Disease after the Introduction of Protein

Vaccination News Home Page                                            subscribe Vaccination NewsLetter

 

http://content.nejm.org/cgi/content/abstract/348/18/1737

 

 

The New England Journal of Medicine
HOME   |   SEARCH   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   HELP
 
Original Article
PreviousPrevious
Volume 348:1737-1746 May 1, 2003 Number 18
NextNext

 

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine
 

Cynthia G. Whitney, M.D., M.P.H., Monica M. Farley, M.D., James Hadler, M.D., M.P.H., Lee H. Harrison, M.D., Nancy M. Bennett, M.D., Ruth Lynfield, M.D., Arthur Reingold, M.D., Paul R. Cieslak, M.D., Tamara Pilishvili, M.P.H., Delois Jackson, M.S.A., Richard R. Facklam, Ph.D., James H. Jorgensen, Ph.D., Anne Schuchat, M.D., for the Active Bacterial Core Surveillance of the Emerging Infections Program Network

 

 
Article
- Table of Contents
- Full Text of this article
- PDF of this article
- PDA version of this article
- Editor's Summary
- CME Exam
- Find Similar Articles in the Journal
- Notify a friend about this article
- Journal Watch (General) Summary
 
- Journal Watch Pediatrics and Adolescent Medicine Summary
 
Services
- Add to Personal Archive
- Download to Citation Manager
- Alert me when letters appear
- Alert me when this article is cited
Medline
- Related Articles in Medline
Articles in Medline by Author:
- Whitney, C. G.
- Medline Citation
Collections
- Infectious Diseases
 
- Child Health
 
- Vaccines
 
- Related Chapters at Harrison's Online
 

ABSTRACT

Background In early 2000, a protein–polysaccharide conjugate vaccine targeting seven pneumococcal serotypes was licensed in the United States for use in young children.

Methods We examined population-based data from the Active Bacterial Core Surveillance of the Centers for Disease Control and Prevention to evaluate changes in the burden of invasive disease, defined by isolation of Streptococcus pneumoniae from a normally sterile site. Serotyping and susceptibility testing of isolates were performed. We assessed trends using data from seven geographic areas with continuous participation from 1998 through 2001 (population, 16 million).

Results The rate of invasive disease dropped from an average of 24.3 cases per 100,000 persons in 1998 and 1999 to 17.3 per 100,000 in 2001. The largest decline was in children under two years of age. In this group, the rate of disease was 69 percent lower in 2001 than the base-line rate (59.0 cases per 100,000 vs. 188.0 per 100,000, P<0.001); the rate of disease caused by vaccine and vaccine-related serotypes declined by 78 percent (P<0.001) and 50 percent (P<0.001), respectively. Disease rates also fell for adults; as compared with base line, the rate of disease in 2001 was 32 percent lower for adults 20 to 39 years of age (7.6 cases per 100,000 vs. 11.2 per 100,000, P<0.001), 8 percent lower for those 40 to 64 years of age (19.7 per 100,000 vs. 21.5 per 100,000, P=0.03), and 18 percent lower for those 65 years of age or more (49.5 per 100,000 vs. 60.1 per 100,000, P<0.001). The rate of disease caused by strains that were not susceptible to penicillin was 35 percent lower in 2001 than in 1999 (4.1 cases per 100,000 vs. 6.3 per 100,000, P<0.001).

Conclusions The use of the pneumococcal conjugate vaccine is preventing disease in young children, for whom the vaccine is indicated, and may be reducing the rate of disease in adults. The vaccine provides an effective new tool for reducing disease caused by drug-resistant strains.

 


Source Information

From the Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta (C.G.W., T.P., D.J., R.R.F., A.S.); Emory University School of Medicine and the Veterans Affairs Medical Center, Atlanta (M.M.F.); the Connecticut Department of Public Health, Hartford (J.H.); Johns Hopkins University Bloomberg School of Public Health, Baltimore (L.H.H.); the Monroe County Department of Health and the University of Rochester, Rochester, N.Y. (N.M.B.); the Minnesota Department of Health, Minneapolis (R.L.); the School of Public Health, University of California, Berkeley (A.R.); the Oregon Department of Human Services, Health Division, Portland (P.R.C.); and the University of Texas Health Science Center, San Antonio (J.H.J.).

Address reprint requests to Dr. Whitney at CDC Mailstop C-23, 1600 Clifton Rd. NE, Atlanta, GA 30333, or at cwhitney@cdc.gov.

 

 

Full Text of this Article


This article has been cited by other articles:

 

  • (2003). Conjugated Pneumococcal Vaccine -- Another Public Health Coup!. Journal Watch Pediatrics and Adolescent Medicine 2003: 5-5 [Full Text]  
  • (2003). Declines in Invasive Pneumococcal Disease Attributed to Vaccines. Journal Watch (General) 2003: 2-2 [Full Text]  


 

HOME   |   SEARCH   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   HELP

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2003 Massachusetts Medical Society. All rights reserved.

 

Vaccination News Home Page

 

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.